UK markets closed

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.5100+0.0300 (+2.03%)
At close: 04:00PM EDT
1.5400 +0.03 (+1.99%)
After hours: 07:42PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 143.40M
Enterprise value -31.87M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.98
Price/book (mrq)5.04
Enterprise value/revenue -0.44
Enterprise value/EBITDA 0.33

Trading information

Stock price history

Beta (5Y monthly) 0.69
52-week change 3-47.75%
S&P500 52-week change 3-10.33%
52-week high 33.0200
52-week low 31.1700
50-day moving average 32.2169
200-day moving average 31.7579

Share statistics

Avg vol (3-month) 32.68M
Avg vol (10-day) 31.3M
Shares outstanding 566.23M
Implied shares outstanding 6N/A
Float 855.13M
% held by insiders 11.46%
% held by institutions 157.77%
Shares short (14 Mar 2023) 41.88M
Short ratio (14 Mar 2023) 41.92
Short % of float (14 Mar 2023) 42.88%
Short % of shares outstanding (14 Mar 2023) 42.85%
Shares short (prior month 14 Feb 2023) 41.38M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022


Profit margin -186.82%
Operating margin (ttm)-176.13%

Management effectiveness

Return on assets (ttm)-19.50%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)53.16M
Revenue per share (ttm)0.81
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)53.16M
EBITDA -91.19M
Net income avi to common (ttm)-99.32M
Diluted EPS (ttm)-1.5000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)193.65M
Total cash per share (mrq)2.92
Total debt (mrq)18.06M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.55
Book value per share (mrq)-1.29

Cash flow statement

Operating cash flow (ttm)-110.79M
Levered free cash flow (ttm)-8.8M